These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1549 related articles for article (PubMed ID: 24525232)

  • 1. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.
    Choi W; Porten S; Kim S; Willis D; Plimack ER; Hoffman-Censits J; Roth B; Cheng T; Tran M; Lee IL; Melquist J; Bondaruk J; Majewski T; Zhang S; Pretzsch S; Baggerly K; Siefker-Radtke A; Czerniak B; Dinney CP; McConkey DJ
    Cancer Cell; 2014 Feb; 25(2):152-65. PubMed ID: 24525232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.
    Choi W; Czerniak B; Ochoa A; Su X; Siefker-Radtke A; Dinney C; McConkey DJ
    Nat Rev Urol; 2014 Jul; 11(7):400-10. PubMed ID: 24960601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
    McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
    Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular subtyping of invasive bladder cancer: time to divide and rule?
    Hurst CD; Knowles MA
    Cancer Cell; 2014 Feb; 25(2):135-6. PubMed ID: 24525229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetics: what do breast and bladder cancer have in common?
    Hutchinson L
    Nat Rev Clin Oncol; 2014 Apr; 11(4):179. PubMed ID: 24569446
    [No Abstract]   [Full Text] [Related]  

  • 6. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
    Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival.
    Helal DS; Darwish SA; Awad RA; Ali DA; El-Guindy DM
    Diagn Pathol; 2023 Feb; 18(1):11. PubMed ID: 36737799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new way of thinking about bladder cancer.
    Black P
    Urology; 2014 Dec; 84(6):1265-6. PubMed ID: 25312552
    [No Abstract]   [Full Text] [Related]  

  • 9. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.
    ; ; ; ; ; ; ; ; Griffiths G; Hall R; Sylvester R; Raghavan D; Parmar MK
    J Clin Oncol; 2011 Jun; 29(16):2171-7. PubMed ID: 21502557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling.
    Takata R; Katagiri T; Kanehira M; Tsunoda T; Shuin T; Miki T; Namiki M; Kohri K; Matsushita Y; Fujioka T; Nakamura Y
    Clin Cancer Res; 2005 Apr; 11(7):2625-36. PubMed ID: 15814643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of neoadjuvant chemotherapy on health-related quality of life in patients with muscle-invasive bladder cancer: results from JCOG0209, a randomized phase III study.
    Kitamura H; Hinotsu S; Tsukamoto T; Shibata T; Mizusawa J; Kobayashi T; Miyake M; Nishiyama N; Kojima T; Nishiyama H;
    Jpn J Clin Oncol; 2020 Dec; 50(12):1464-1469. PubMed ID: 32699909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer.
    Sternberg CN; Parmar MK
    J Clin Oncol; 2001 Sep; 19(18 Suppl):21S-26S. PubMed ID: 11560967
    [No Abstract]   [Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy in transitional-cell carcinoma of the bladder.
    McLaren DB
    Clin Oncol (R Coll Radiol); 2005 Oct; 17(7):503-7. PubMed ID: 16238137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscle-invasive urothelial carcinoma of the bladder: neoadjuvant chemotherapy enables organ-preserving therapy in carefully selected patients.
    Heidenreich A
    Eur Urol; 2008 Jul; 54(1):21-3. PubMed ID: 18262722
    [No Abstract]   [Full Text] [Related]  

  • 15. Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis.
    de Jong JJ; Liu Y; Robertson AG; Seiler R; Groeneveld CS; van der Heijden MS; Wright JL; Douglas J; Dall'Era M; Crabb SJ; van Rhijn BWG; van Kessel KEM; Davicioni E; Castro MAA; Lotan Y; Zwarthoff EC; Black PC; Boormans JL; Gibb EA
    Genome Med; 2019 Oct; 11(1):60. PubMed ID: 31619281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
    Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
    J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
    Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
    Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.
    Kilari D; Iczkowski KA; Pandya C; Robin AJ; Messing EM; Guancial E; Kim ES
    Anticancer Res; 2016 Feb; 36(2):495-501. PubMed ID: 26851002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.
    Metcalfe MJ; Ferguson JE; Li R; Xiao L; Guo CC; Czerniak BA; Siefker-Radtke A; Pretzsch SM; Navai N; McConkey DJ; Kamat AM; Campbell M; Dinney C
    Eur Urol Focus; 2017 Dec; 3(6):577-583. PubMed ID: 28753816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
    Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
    Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 78.